We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immunoassay Evaluated For Tularemia Diagnosis

By LabMedica International staff writers
Posted on 12 Sep 2012
The laboratory diagnosis of tularemia is usually based on direct detection of the bacteria either by culture or by nucleic acid amplification techniques and on detection of elevated antibody titers. More...


A simple, rapid, and affordable point-of-care immunochromatographic assay has been evaluated that may assist in narrowing the differential diagnosis and would be useful for early diagnosis and treatment and for public health surveillance.

Scientists at Public Health Institution (Ankara, Turkey) tested a panel of 221 sera from 109 cases of tularemia as well as 236 sera from normal individuals or individuals with other infectious or autoimmune diseases. A commercially available immunochromatographic assay (ICA) for the serologic diagnosis of tularemia was evaluated, and the performance was compared with that of the current standard, the microagglutination test (MAT).

The VIRapid Tularemia ICA (Vircell; Granada, Spain) was manufactured using lipopolysaccharides (LPS) extracted by the hot phenol–water method from Francisella tularensis cell suspension. LPS was adsorbed on both the conjugate and the test line to generate a lateral flow ICA. A control line was also included to check the correct performance of the test. The test was performed by the addition of serum to the sample pad of the assay device followed by the addition of running fluid. Test results were read after 15 minutes by visual inspection for staining of the antigen and control lines. The intensity of staining of the reaction band was read visually and scored from one to three with a color reference diagram.

The ICA demonstrated 91.5% agreement with the MAT reference method and gave an overall sensitivity of 99.3% and a specificity of 94.6%. When only acute-phase sera were considered, the sensitivity and specificity of the ICA were 100% and 95.5%, respectively. No cross-reactivity was observed in the ICA with serum samples from normal individuals and patients with autoimmune diseases and bacterial, viral, and parasitic infections, although 4 out of 50 patients with brucellosis demonstrated positive results in the ICA.

The authors concluded that ICA showed higher positivity with early acute-phase sera than the reference MAT, while retaining high specificity. The assay should greatly improve the rapid detection of tularemia in the field and facilitate the rapid determination of the extent of public health threat especially in outbreak situations. Tularemia is an infection caused by F. tularensis, a Gram-negative, nonmotile coccobacillus, with a worldwide distribution in the northern hemisphere and diverse clinical manifestations. Humans become infected through arthropod bites, handling of infected animal tissues, or ingestion of contaminated water or food, and inhalation of infectious aerosols. The study was published in the September 2012 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Public Health Institution of Turkey
Vircell



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.